Approval · Notice of Compliance 833 · 2002
REMODULIN: Notice of Compliance 833
Issued October 4, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 833
- Date
- October 4, 2002
- Company
- United Therapeutics CorporationDurham, North Carolina, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Vasodilator
Products in this notice
Medicinal ingredients
- TREPROSTINIL SODIUM 1 MG per ML
- TREPROSTINIL SODIUM 2.5 MG per ML
- TREPROSTINIL SODIUM 5 MG per ML
- TREPROSTINIL SODIUM 10 MG per ML